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A
utoimmune type 1 diabetes is caused by an
interactive combination of genetic and environ-
mental factors, most of which remain un-
known. Each individual appears to have a
unique combination of these factors that allow for their
susceptibility to disease. Investigators have long searched
for physiological mechanisms that could link diverse en-
vironmental events to inheritable genetic traits and the
aberrant gene expression in immune cells. Much of this
search has focused on either uncovering elusive gene
polymorphisms found in at-risk populations or on ﬁnding
common elements in the lives of susceptible individuals
that “trigger” their immune system toward a self-destruc-
tive path (1,2). To date, only a few gene polymorphisms
have linked to susceptibility, with none so far proven both
essential and sufﬁcient to promote disease (1). The search
for environmental etiological agents in this multifactorial
disease has been no less difﬁcult, since each individual
afﬂicted appears to have a unique set of factors promoting
autoimmunity rather than a single or few common triggers
(2). So how can such a diverse set of environmental
stimulators rapidly and reversibly trigger a variety of
undeﬁned genetic regions to promote the loss of some-
thing as basic to normal physiology as tolerance of self? Is
there a common mechanism even when the end targets are
elusive and environmental slings and arrows are so di-
verse? Enter epigenetic gene regulation into the tableau,
adding a new meaning to the term genetic susceptibility
(Fig. 1).
The Human Genome Project gave us the revelation that
most of the genome is made up of noncoding regions that
are responsible in some way for the preservation and
regulation of the small portion of the genome that encodes
gene products (3). Chromatin shape changes in these
nontranscribed regions that promote DNA accessibility
play a pivotal role in control of genes in both local and
distant regions along the chromosome (4). Inheritable and
reversible changes in chromatin topology are actively
promoted by reversible enzymatic modiﬁcation of histones
and DNA with small molecules (e.g., acetylation, ubiquiti-
nation, sumolation, and methylation) in response to signal
transduction, allowing gene expression, DNA repair, and
DNA replication enzymes to have access to DNA within
large regions of chromatin (5–8). Acetylation/deacetyla-
tion of histones allows for temporary open and closing
chromatin topology, whereas histone methylation modiﬁ-
cations yield more stable change in chromatin accessibil-
ity. These epigenetic modiﬁcations occur in rapid
response to environmental triggers such as viral infection
and endotoxin promulgated through cytokine, hormonal,
and antigen signaling, which all have the potential to promote
both establishment and loss of immune tolerance (8).
Animal and human genetic studies (9–12) of type 1
diabetes have deﬁned genetic regions associated with
disease susceptibility and resistance. Often, studies of
these regions have uncovered that the polymorphisms
associated with disease susceptibility or resistance are
found in nontranscribed regulatory regions rather than
within the gene-coding regions. Congenic breeding analy-
sis of Idd loci in nonobese diabetic (NOD) mice has
brought to light phenomenon of gene expression cluster-
ing in autoimmune susceptibility, such as Idd loci contain-
ing multiple members in a single pathway (e.g.,
interleukin-2 signaling components on Chr3/Idd3 and
Idd10 [10] and the major histocompatibility complex
Chr17/Idd1 [11]) or genes whose products support similar
functions (e.g., cytokine gene cluster on Chr 11/Idd4.3
[12]). These ﬁndings suggest that aberration of a regional
regulatory control mechanism may be underlying the
association of the entire locus with type 1 diabetes.
Epigenetic modiﬁcations of histones and DNA that regu-
late chromatin structure and accessibility of proteins to
transcription regulatory regions would be likely candi-
dates for such a regional control mechanism.
Changes in Lys9 methylation in islet stem cells are
associated with insulin secretion potential (13). Recent
compelling evidence (14) suggests that microsatellite RNA
involved in autoimmune susceptibility are located in epi-
genetic hot spots and implicate their dysregulation in the
pathology of rheumatoid arthritis. STAT proteins, which
are activated by cytokines and hormones to act as adaptor
proteins for histone modiﬁcation acetylases and deacety-
lases, have linked epigenetic dysfunction with autoimmu-
nity including STAT3 dysregulation in B-cells in lupus (15),
STAT6 function in B-cell dysfunction in Sjo ¨gren’s disease
(16), and STAT5 dysfunction with aberrant cytokine sig-
naling in inﬂammation, regulatory T-cell activation, and
myeloid cell functional maturation in type 1 diabetes
(17,18).
The work of Maio et al. (19) in this issue of Diabetes
provides further evidence that dysregulation of epigenetic
modiﬁcation is associated with type 1 diabetes. These
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COMMENTARY
3184 DIABETES, VOL. 57, DECEMBER 2008studies show that histone methylation is signiﬁcantly
increased in nontranscribed regulatory regions near or
within human type 1 diabetes susceptibility regions, in-
cluding loci containing the gene for CLTA4 and genes in
inﬂammation-associated pathways. These elegant bioin-
formatic ChIP-on-CHIP–based studies shed needed light
on the importance of regional chromatin control in re-
sponse to environmental stimuli and highlight the path-
ways most responsive in type 1 diabetes susceptibility,
including T-cell anergy, inﬂammation, and innate response
signaling networks. However, the ChIP selection here is
limited to one, albeit important, modiﬁcation—Lys9—and
was not functionally tested. Still, these intriguing data
parallel the 2005 studies by Wren and Garner (20), which
found that epigenetic changes in proinﬂammatory and
cytokine genes were among the highest statistical scoring
target hits in their analysis of type 2 diabetes pathogenesis.
Both these studies fall short of making the functional link
between these modiﬁcations and the genes they may
affect. However, together with the phenotypic studies that
proceeded them, these ﬁndings suggest pathway candi-
dates and give a starting point for investigation of the
potential role for epigenetic gene regulation in insulin
signaling and inﬂammation in the shared etiology for both
type 1 and type 2 diabetes. In addition, these genome-wide
scans provide a roadmap for future functional studies
linking environmental triggers to genetic dysregulation in
autoimmunity. Deﬁning dysfunctional epigenetic gene reg-
ulation’s potential as a more global mechanism for suscep-
tibility may lead to a shift in the way we approach
treatment and prevention of autoimmune pathologies and
other multifactorial diseases. For diabetes, the discovery
of defects in epigenetic modiﬁcation in control of suscep-
tibility loci makes it one of the strongest candidates for
that elusive “missing link” of autoimmune disease re-
search: a mechanism common to and potentially linking
both environment stimulation and genetic susceptibility in
immunopathogenesis.
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